Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) have been given an average rating of “Moderate Buy” by the twenty-four analysts that are covering the company, Marketbeat reports. Five equities research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $163.91.

A number of analysts recently issued reports on the company. BMO Capital Markets lowered their target price on Neurocrine Biosciences from $128.00 to $114.00 and set a “market perform” rating for the company in a research note on Thursday, October 17th. Jefferies Financial Group raised their price objective on shares of Neurocrine Biosciences from $177.00 to $189.00 and gave the stock a “buy” rating in a report on Monday, August 19th. Piper Sandler raised shares of Neurocrine Biosciences from a “neutral” rating to an “overweight” rating and upped their target price for the stock from $131.00 to $159.00 in a research note on Thursday, August 29th. Citigroup lifted their price target on Neurocrine Biosciences from $150.00 to $158.00 and gave the company a “neutral” rating in a research note on Friday, August 2nd. Finally, JPMorgan Chase & Co. boosted their price target on Neurocrine Biosciences from $173.00 to $181.00 and gave the company an “overweight” rating in a report on Wednesday, August 7th.

Institutional Investors Weigh In On Neurocrine Biosciences

A number of large investors have recently added to or reduced their stakes in the business. Ashton Thomas Private Wealth LLC acquired a new position in shares of Neurocrine Biosciences in the second quarter valued at $28,000. Innealta Capital LLC acquired a new position in Neurocrine Biosciences in the 2nd quarter valued at about $30,000. New Covenant Trust Company N.A. acquired a new position in Neurocrine Biosciences in the 1st quarter valued at about $32,000. EdgeRock Capital LLC bought a new position in Neurocrine Biosciences in the 2nd quarter valued at about $35,000. Finally, Blue Trust Inc. lifted its position in Neurocrine Biosciences by 171.9% during the third quarter. Blue Trust Inc. now owns 348 shares of the company’s stock worth $40,000 after acquiring an additional 220 shares during the last quarter. Institutional investors own 92.59% of the company’s stock.

Neurocrine Biosciences Stock Up 1.2 %

Shares of NASDAQ NBIX opened at $127.11 on Tuesday. Neurocrine Biosciences has a twelve month low of $110.52 and a twelve month high of $157.98. The stock has a market cap of $12.87 billion, a price-to-earnings ratio of 34.08 and a beta of 0.35. The company’s fifty day moving average is $118.62 and its 200-day moving average is $131.89.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.